Skip to main content

Canadian Patent granted for BUPI

STOCKHOLM, September 1st 2017, Moberg Pharma AB (OMX: MOB) announced that the Canadian Patent Office (CIPO) has issued Patent No. 2 860 373 which protects BUPI, currently in development for pain due to oral mucositis. This patent is expected to provide coverage through at least 2032.

The Canadian patent covers the use of a lozenge comprising a local anesthetic, e.g. bupivacaine, in a number of different indication, including treatment of pain due to oral mucositis in cancer patients. This patent is expected to provide coverage through at least 2032. Moberg Pharma has previously announced patent protection in Europe and an additional patent application is pending in the United States.

“This issuance of this patent is an important part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products.” commented Peter Wolpert, Moberg Pharma’s CEO.

In 2016, Moberg Pharma announced positive Phase 2 results with BUPI in treating pain associated with oral mucositis in patients with head and neck cancer undergoing radiotherapy. Recently, an application for a phase 3 study has been submitted by Cadila Pharmaceuticals, Moberg Pharma's partner, responsible for financing and implementing the current phase 3 study in India. Moberg Pharma estimates that the product has a sales potential amounting to USD 50–100 million annually, assuming successful commercialization in oral mucositis and at least one further indication.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1.30 p.m. (CET) on September 1st 2017.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail:
Anna Ljung, CFO, telephone: +46 707 66 60 30, E-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).